MAPT and Alzheimer disease: Though these studies have primarily focused on AD, the significant potential of incretin-based medications in modulating amyloid and tau pathologies, which are a part of the pathophysiology of severe brain injury, points to another plausible mechanism by which these medications might promote recovery from DOC.